Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. by Piaggio, Gilda et al.
Piaggio, G; Elbourne, DR; Altman, DG; Pocock, SJ; Evans, SJ (2006)
Reporting of noninferiority and equivalence randomized trials: an ex-
tension of the CONSORT statement. JAMA, 295 (10). pp. 1152-60.
ISSN 0098-7484 DOI: https://doi.org/10.1001/jama.295.10.1152
Downloaded from: http://researchonline.lshtm.ac.uk/12069/
DOI: 10.1001/jama.295.10.1152
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
SPECIAL COMMUNICATION
Reporting of Noninferiority
and Equivalence Randomized Trials
An Extension of the CONSORT Statement
Gilda Piaggio, PhD
Diana R. Elbourne, PhD
Douglas G. Altman, DSc
Stuart J. Pocock, PhD
Stephen J. W. Evans, MSc
for the CONSORT Group
THE CONSOLIDATED STAN-dards of Reporting Trials(CONSORT) statement wasdeveloped to alleviate the
problem of inadequate reporting
of randomized controlled trials
(RCTs),1-4 which has been associated
with biased treatment effects.5-7 The
statement comprises evidence-based
recommendations for reporting
RCTs, including a flowchart of par-
ticipants through the trial.
CONSORT’s primary focus is on par-
allel group trials,1-3 aiming to identify
treatment superiority if it really exists.
Most CONSORT recommendations ap-
ply equally well to other trial designs,
but some need adaptation. Herein we
extend the CONSORT recommenda-
tions to noninferiority and equiva-
lence trials. First, we explain the ratio-
nale for and key methodological
features of such trials. Second, we con-
sider how commonly noninferiority and
equivalence trials are published and
provide empirical evidence about their
quality. Last, we present an adapted
CONSORT checklist for reporting non-
inferiority and equivalence trials and
give illustrative examples (and further
elaboration) for those items that have
been amended.
For convenience, we will refer to
treatments and patients, although we
recognize that not all interventions
evaluated in RCTs are technically treat-
ments and the participants in trials are
not always patients.
Rationale for Noninferiority
or Equivalence Designs
Most RCTs aim to determine whether
one intervention is superior to an-
other. By contrast, equivalence trials8
aim to determine whether one (typi-
cally new) intervention is therapeuti-
cally similar to another, usually an ex-
isting treatment. We use new to refer
to the treatment under test, and the
comparison or reference treatment is of-
ten called an active control.
A noninferiority trial seeks to deter-
mine whether a new treatment is no
See also pp 1147 and 1172.
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The CONSORT (Consolidated Standards of Reporting Trials) Statement, in-
cluding a checklist and a flow diagram, was developed to help authors im-
prove their reporting of randomized controlled trials. Its primary focus was
on individually randomized trials with 2 parallel groups that assess the pos-
sible superiority of one treatment compared with another but is now being
extended to other trial designs. Noninferiority and equivalence trials have
methodological features that differ from superiority trials and present par-
ticular difficulties in design, conduct, analysis, and interpretation. Although
the rationale for such trials occurs frequently, those designed and described
specifically as noninferiority or equivalence trials appear less commonly in
the medical literature. The quality of reporting of those that are published is
often inadequate. In this article, we present an adapted CONSORT check-
list for reporting noninferiority and equivalence trials and provide illustra-
tive examples and explanations for those items amended from the original
CONSORT checklist. The intent is to improve reporting of noninferiority and
equivalence trials, enabling readers to assess the validity of their results and
conclusions.
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worse than a reference treatment. Be-
cause proof of exact equality is impos-
sible, a prestated margin of noninferi-
ority () for the treatment effect in a
primary patient outcome is defined.
Equivalence trials are very similar, ex-
cept that equivalence is defined as the
treatment effect being between − and
. True (2-sided) equivalence thera-
peutic or prophylactic trials are rare be-
cause most such trials address the ques-
tion of noninferiority.
In trials that investigate noninferi-
ority, the question of interest is not sym-
metric.9 The new treatment will be rec-
ommended if it is similar to or better
than an existing one, but not if it is
worse (by more than). Superiority of
the new treatment would be a bonus.
This article focuses mainly on nonin-
feriority trials but applies also to 2-sided
equivalence trials.
Noninferiority trials are intended to
show whether a new treatment has at
least as much efficacy as the standard
or is worse by an amount less than ,
often on the premise that it has some
other advantage, eg, greater availabil-
ity, reduced cost, less invasive-
ness,10,11 fewer side effects (harms),12 or
greater ease of administration,13 for in-
stance, one daily dose rather than 2
doses14 or more than 2 doses.15 Some
noninferiority trials have been criti-
cized for merely studying a new mar-
ketable product (“me-too” drugs).16
Noninferiority and equivalence trials
are not limited to drugs. For example,
a new antenatal care model with fewer
clinic visits and reduced cost was in-
vestigated for its equivalence to the stan-
dard model as regards maternal and
neonatal outcomes.17 A noninferiority
trial compared 2 interventional strate-
gies for coronary revascularization in
diabetic patients.18
Methodological Issues
in Noninferiority and
Equivalence Trials
Noninferiority and equivalence trials pre-
sent particular difficulties in design, con-
duct, analysis, and interpretation.19
Hypotheses. In a superiority trial the
null hypothesis is that treatments are
equally effective and the alternative hy-
pothesis is that they differ. A type I er-
ror is falsely finding a treatment effect
when there is none, and a type II error
is failing to detect a treatment effect
when truly one exists. In noninferior-
ity trials, the null and alternative hy-
potheses are reversed; a type I error is
the erroneous acceptance of an infe-
rior new treatment, whereas a type II
error is the erroneous rejection of a truly
noninferior treatment.
Design. A noninferiority or equiva-
lence trial requires that the reference
treatment’s efficacy is established20,21 or
is in widespread use so that a placebo
or untreated control group would be
deemed unethical.
Both participants and outcome mea-
sures in a noninferiority or equiva-
lence trial should be similar to those in
trial(s) that established the efficacy of
the reference treatment. Outcome mea-
sures should also be similar to those in
previous trials.
The required sample size is calcu-
lated using the confidence interval
(CI) approach, considering where the
CI for the treatment effect lies with
respect to both the margin of noninfe-
riority  and a null effect. Sample size
depends on the level of confidence
chosen, the risk of type II error (or
desired power), and .22,23 A prestated
margin of noninferiority  can be
specified as a difference in means or
proportions or the logarithm of an
odds ratio, risk ratio, or hazard ratio.
A prestated margin of noninferiority is
often chosen as the smallest value that
would be a clinically important
effect.24 If relevant,  should be
smaller than the “clinically relevant”
effect chosen to investigate superiority
of reference treatment against pla-
cebo.25,26 For example, if mortality
with treatment A is better than pla-
cebo by 10% (absolute difference), a
new treatment B might need to be at
least 5% better than placebo (and thus
no more than 5% worse than A). The
required size of noninferiority trials is
therefore usually larger than that for
superiority trials.25 Unfortunately,
sample sizes for noninferiority and
equivalence trials are often too
small.19,24 Given several previous trials,
the effect of the reference treatment
can be estimated from a meta-analysis.
There are several techniques to deter-
mine ,27 its magnitude being influ-
enced by several factors, eg, efficacy,
safety, cost, acceptability, and adher-
ence.28,29
Conduct. Trial conduct should
closely match any trial that demon-
strated efficacy of the reference treat-
ment, provided they were of high qual-
ity.20 One should avoid features that
might dilute true differences between
treatments, thereby enhancing the risk
of erroneously concluding noninferi-
ority,30,31 eg, poor adherence, drop-
outs, recruitment of patients unlikely
to respond, and treatment crossovers.
Analysis. Although a modified hy-
pothesis testing framework exists,32,33
a more informative CI approach is pre-
ferred in the design, analysis, and re-
porting of noninferiority and equiva-
lence trials.34
For superiority trials, intention-to-
treat (ITT) analysis (analyzing all
patients within their randomized
groups, regardless of whether they
completed allocated treatment) is rec-
ommended.3 Intention-to-treat analy-
sis often leads to smaller observed
treatment effects than if all patients
had adhered to treatment. In non-
inferiority trials, ITT analysis will
often increase the risk of falsely claim-
ing noninferiority (type I error),25
although not always.35 In practice, ITT
analysis is often not possible and one
uses a “full analysis set” to describe
that patient follow-up, which is “as
complete . . . and . . . close as possible”
to ITT.36
Alternative analyses that exclude pa-
tients not taking allocated treatment or
otherwise not protocol-adherent could
bias the trial in either direction.37 The
terms on-treatmentor per-protocol analy-
sis are often used but may be inad-
equately defined. Potentially biased
non-ITT analysis is less desirable than
ITT in superiority trials but may still
provide some insight. In noninferior-
ity and equivalence trials, non-ITT
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analyses might be desirable as a pro-
tection from ITT’s increase of type I er-
ror risk (falsely concluding noninferi-
ority).36 There is greater confidence in
results when the conclusions are
consistent.
Subgroup analysis requires the same
caveats in noninferiority trials as it re-
quires in superiority trials. Interim
analyses in noninferiority trials have
some differences in rationale from su-
periority trials. If noninferiority is es-
tablished before the trial is completed,
there may be no ethical requirement to
stop early because of lack of efficacy.19
However, other advantages (adverse ef-
fects, cost) could justify stopping the
trial, to expedite availability of the new
treatment. If a treatment is clearly in-
ferior, then stopping the trial (or a par-
ticular trial arm) is ethically justi-
fied.38-40 Stopping rules might be
asymmetric, a trial being allowed to
continue longer if the new treatment ap-
pears superior,41 although this result is
unlikely.19
Interpretation. Interpreting a non-
inferiority trial’s results depends on
where the CI for the treatment effect lies
relative to both the margin of noninfe-
riority  and a null effect. The ob-
served treatment effect is not by itself
sufficiently informative. With 2-sided
equivalence the interpretation is analo-
gous, but both margins and − need
considering, and claiming equiva-
lence requires the CI to lie wholly be-
tween − and .
Many noninferiority trials based
their interpretation on the upper limit
of a 1-sided 97.5% CI, which is the
same as the upper limit of a 2-sided
95% CI. Although both 1-sided and
2-sided CIs allow for inferences about
noninferiority, we suggest that 2-sided
CIs are appropriate in most noninferi-
ority trials.29 If a 1-sided 5% signifi-
cance level is deemed acceptable for
the noninferiority hypothesis test42 (a
decision open to question), a 90%
2-sided CI could then be used. The
FIGURE interprets several possible
scenarios with 2-sided CIs for a non-
inferiority trial.
Once noninferiority is evident, it is
acceptable to then assess whether the
new treatment appears superior to the
reference treatment, using an appro-
priate test or CI (ie, not just the point
estimate), preferably defined a priori
and with an ITT analysis.22,28,43
It is inappropriate to claim noninfe-
riority post hoc from a superiority trial
unless clearly related to a predefined
margin of equivalence. That is, both su-
periority and noninferiority hypoth-
eses need explicit specification in the
trial protocol.44 It is, however, always
reasonable to interpret a CI as exclud-
ing an effect of a particular prestated
size.45 Having demonstrated noninfe-
riority against reference treatment, some
authors then make claims for efficacy
of a new treatment relative to placebo
by also using evidence from earlier trials
of reference treatment vs placebo.46
Such inferences assume assay con-
stancy, ie, current and earlier trials are
identical in all relevant aspects,20 eg,
participants, outcomes definition, and
use of standard therapy. Regarding pa-
tient populations, for example, this im-
plies no differences in the effect of treat-
ment across subgroups or similar
distribution of relevant subgroups. In
the absence of assay constancy, an ad-
justment method has been pro-
posed.27 Since assay constancy is inevi-
tably questionable, any claims regarding
efficacy of new treatment relative to pla-
cebo require cautious interpretation.
How Common Are
Noninferiority and
Equivalence Trials?
Assessing the frequency of noninferi-
ority and equivalence trials is not
Figure. Possible Scenarios of Observed Treatment Differences for Adverse Outcomes (Harms)
in Noninferiority Trials
Treatment Difference for Adverse Outcome
(New Treatment Minus Reference Treatment)
N E W  T R E AT M E N T  W O R S EN E W  T R E AT M E N T  B E T T E R
∆0
Superior
A
Noninferior
B
Noninferior
C
Noninferior?∗
D
Inconclusive
E
Inconclusive
F
Inconclusive?†
G
Inferior
H
Error bars indicate 2-sided 95% confidence intervals (CIs). Tinted area indicates zone of inferiority. A, If the CI
lies wholly to the left of zero, the new treatment is superior. B and C, If the CI lies to the left of  and includes
zero, the new treatment is noninferior but not shown to be superior. D, If the CI lies wholly to the left of  and
wholly to the right of zero, the new treatment is noninferior in the sense already defined, but it is also inferior
in the sense that a null treatment difference is excluded. This puzzling case is rare, since it requires a very large
sample size. It can also result from having too wide a noninferiority margin. E and F, If the CI includes  and
zero, the difference is nonsignificant but the result regarding noninferiority is inconclusive. G, If the CI includes
 and is wholly to the right of zero, the difference is statistically significant but the result is inconclusive re-
garding possible inferiority of magnitude  or worse. H, If the CI is wholly above , the new treatment is in-
ferior.22,43
*This CI indicates noninferiority in the sense that it does not include , but the new treatment is significantly
worse than the standard. Such a result is unlikely because it would require a very large sample size.
†This CI is inconclusive in that it is still plausible that the true treatment difference is less than , but the new
treatment is significantly worse than the standard.
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straightforward because of inconsis-
tencies in terminology. A search of
the Cochrane Controlled Trials Regis-
ter47 in October 2004 for the words
equivalence or noninferiority yielded
1021 of 415 918 trials (0.2%), but
these figures are likely to be mislead-
ing. Not all noninferiority or equiva-
lence trials use these words, and the
term equivalence is often inappropri-
ately used when reporting negative
results of superiority trials; such trials
often lack statistical power to rule out
important differences.48,49 Identifying
noninferiority trials is difficult because
they are often labeled as equivalence
trials. A recent study50 found that
only 3 of 188 (1.6%) cancer trials in
a PubMed electronic search were
designed to evaluate equivalence or
noninferiority (Luciano Costa, MD,
written communication, April 26,
2005).
From the above findings, it seems
that whereas the objective of testing for
noninferiority or equivalence is likely
to be common, there have been rela-
tively few noninferiority and equiva-
lence trials that are both designed and
described as such. However, we per-
ceive that these designs are becoming
more widespread.
Quality of Reporting
of Noninferiority and
Equivalence Trials
We do not know of a study that looked
at reporting of a cohort of trials actu-
ally designed as noninferiority or
equivalence trials. There have been sev-
eral reviews of quality of trials claim-
ing equivalence, without differentia-
tion between noninferiority and 2-sided
equivalence, because many authors use
the term equivalence to mean either.
Greene et al49 identified method-
ological flaws in a systematic review of
88 studies claiming equivalence, pub-
lished from 1992 to 1996. Equiva-
lence was inappropriately claimed in
67% of them, on the basis of nonsig-
nificant tests for superiority. Fifty-one
percent stated equivalence as an aim,
but only 23% were designed with a pre-
set margin of equivalence. Only 22%
adopted appropriate practice: a pre-
defined aim of equivalence, a preset,
consequent sample size determina-
tion, and actually testing equivalence.
Other disease- or field-specific re-
views reveal similar findings. Only 2
trials (8%) in a review51 of 25 RCTs in
childhood bacterial meningitis pub-
lished between 1980 and 2000 that
claimed equivalent mortality were de-
signed to test equivalence. A review of
90 RCTs with nonstatistically signifi-
cant or “negative” results published in
3 surgical journals from 1988 to 1998
found 39% met predefined criteria for
establishing equivalence.52 Only 3 stud-
ies in a recent review of 188 cancer trials
with negative results used a noninferi-
ority or equivalence analysis.50 In a re-
view of 20 trials intended to detect
equivalence in reproductive health, only
4 stated a margin of equivalence.53
McAlister and Sackett37 evaluated 4
large “negative” RCTs in hyperten-
sion as regards methodological require-
ments for active-control equivalence
trials. Only 2 trials published both ITT
and per-protocol (or on-treatment)
analyses, only 1 trial specified the mar-
gin of equivalence in advance, and none
was sufficiently large to address the
equivalence hypothesis. This illus-
trates how failure to properly design,
conduct, and analyze equivalence trials
leads to incorrect conclusions about
equivalence.
Extension of
Consort Statement
To accommodate noninferiority or
equivalence trials, an extension of the
CONSORT statement should encom-
pass the following issues: (1) the ratio-
nale for adopting a noninferiority or
equivalence design; (2) how study hy-
potheses were incorporated into the de-
sign; (3) choice of participants, inter-
ventions (especially the reference
treatment), and outcomes; (4) statisti-
cal methods, including sample size cal-
culation; and (5) how the design af-
fects interpretation and conclusions.
Consequences for the CONSORT
checklist and flow diagram, including
specific changes, are described below.
Checklist
We build on the work of McAlister and
Sackett37 in modifying the CONSORT
checklist2,3 (TABLE), especially items 1
to 7, 12, 16, 17, and 20. New text is
shown in italics. For each modifica-
tion, we include 1 or more examples of
good reporting (and further elabora-
tion where appropriate). In some ex-
amples, we have added text in brack-
ets to explain the context. We mainly
concentrate on noninferiority trials but
make some reference to equivalence
trials which are much less common.
Title and Abstract
Title and Abstract: Item 1. How par-
ticipants were allocated to interven-
tions (eg, random allocation, random-
ized, or randomly assigned), specifying
that the trial is a noninferiority or equiva-
lence trial.
Title. “Oral Pristinamycin versus
Standard Penicillin Regimen to Treat
Erysipelas in Adults: Randomised, Non-
inferiority, Open Trial”54
Abstract. “Design—Multicentre, par-
allel group, open labelled, randomised
noninferiority trial.”54
Introduction
Background: Item 2. Scientific back-
ground and explanation of rationale, in-
cluding the rationale for using a nonin-
feriority or equivalence design.
Example. “Up to 40 million chil-
dren worldwide are estimated to suf-
fer from vitamin A deficiency. . . . A dose
of 200,000 IU retinyl palmitate to
children over 1 year old is most widely
used and has generally been regarded
as safe and potentially effective. . . . In
developing countries, animal prod-
ucts that provide retinyl esters are
too expensive. . . . Vegetables and
fruit . . . are cheap and good sources
of vitamin A in the form of beta
carotene. . . . Beta carotene is also con-
sidered to be virtually non-toxic. . . . In
a preliminary study, . . . after 20 days
there was a reversion of the clinical and
subclinical signs of vitamin A defi-
ciency in the study group. . . . Since beta
carotene is the principal source of vi-
tamin A in developing countries and is
REPORTING NONINFERIORITY AND EQUIVALENCE
©2006 American Medical Association. All rights reserved. (Reprinted) JAMA, March 8, 2006—Vol 295, No. 10 1155
Downloaded From:  by a London Sch of Hygiene & Tropical Medicine User  on 05/05/2018
Table. Checklist of Items for Reporting Noninferiority or Equivalence Trials (Additions or Modifications to the CONSORT Checklist are Shown
in Italics)
Paper Section and Topic Item Number Descriptor (Adapted for Noninferiority or Equivalence Trials)
Title and abstract 1* How participants were allocated to interventions (eg, “random allocation,” “randomized,”
or “randomly assigned”), specifying that the trial is a noninferiority or equivalence trial.
Introduction
Background 2* Scientific background and explanation of rationale, including the rationale for using a
noninferiority or equivalence design.
Methods
Participants 3* Eligibility criteria for participants (detailing whether participants in the noninferiority or
equivalence trial are similar to those in any trial[s] that established efficacy of the
reference treatment) and the settings and locations where the data were collected.
Interventions 4* Precise details of the interventions intended for each group, detailing whether the
reference treatment in the noninferiority or equivalence trial is identical (or very similar)
to that in any trial(s) that established efficacy, and how and when they were actually
administered.
Objectives 5* Specific objectives and hypotheses, including the hypothesis concerning noninferiority or
equivalence.
Outcomes 6* Clearly defined primary and secondary outcome measures, detailing whether the
outcomes in the noninferiority or equivalence trial are identical (or very similar) to
those in any trial(s) that established efficacy of the reference treatment and, when
applicable, any methods used to enhance the quality of measurements (eg, multiple
observations, training of assessors).
Sample size 7* How sample size was determined, detailing whether it was calculated using a
noninferiority or equivalence criterion and specifying the margin of equivalence with
the rationale for its choice. When applicable, explanation of any interim analyses and
stopping rules (and whether related to a noninferiority or equivalence hypothesis).
Randomization
Sequence generation 8 Method used to generate the random allocation sequence, including details of any
restriction (eg, blocking, stratification).
Allocation concealment 9 Method used to implement the random allocation sequence (eg, numbered containers or
central telephone), clarifying whether the sequence was concealed until interventions
were assigned.
Implementation 10 Who generated the allocation sequence, who enrolled participants, and who assigned
participants to their groups.
Blinding (masking) 11 Whether or not participants, those administering the interventions, and those assessing
the outcomes were blinded to group assignment. When relevant, how the success of
blinding was evaluated.
Statistical methods 12* Statistical methods used to compare groups for primary outcome(s), specifying whether
a 1- or 2-sided confidence interval approach was used. Methods for additional
analyses, such as subgroup analyses and adjusted analyses.
Results
Participant flow 13 Flow of participants through each stage (a diagram is strongly recommended).
Specifically, for each group report the numbers of participants randomly assigned,
receiving intended treatment, completing the trial protocol, and analyzed for the
primary outcome. Describe protocol deviations from trial as planned, together with
reasons.
Recruitment 14 Dates defining the periods of recruitment and follow-up.
Baseline data 15 Baseline demographic and clinical characteristics of each group.
Numbers analyzed 16* Number of participants (denominator) in each group included in each analysis and
whether “intention-to-treat” and/or alternative analyses were conducted. State the
results in absolute numbers when feasible (eg, 10/20, not 50%).
Outcomes and estimation 17* For each primary and secondary outcome, a summary of results for each group and the
estimated effect size and its precision (eg, 95% confidence interval). For the
outcome(s) for which noninferiority or equivalence is hypothesized, a figure showing
confidence intervals and margins of equivalence may be useful.
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including subgroup
analyses and adjusted analyses, indicating those prespecified and those exploratory.
Adverse events 19 All important adverse events or side effects in each intervention group.
Comment
Interpretation 20* Interpretation of the results, taking into account the noninferiority or equivalence
hypothesis and any other trial hypotheses, sources of potential bias or imprecision
and the dangers associated with multiplicity of analyses and outcomes.
Generalizability 21 Generalizability (external validity) of the trial findings.
Overall evidence 22 General interpretation of the results in the context of current evidence.
*Expansion of corresponding item on CONSORT checklist.2,3
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non-toxic, we compared retinyl palmi-
tate and beta carotene for treatment of
vitamin A deficiency.”55
Elaboration.The rationale should cite
evidence for the efficacy of the refer-
ence treatment. If previous trials, or
their systematic review, demonstrate the
superiority of the reference treatment
relative to placebo, they should be cited
with effect sizes and CIs. If no such trials
exist, other evidence for efficacy of the
reference treatment should be given.
Evidence for other advantages of the
new treatment over the reference treat-
ment, if present, should be given, to jus-
tify use of the new treatment, if not in-
ferior. One aim of the current trial might
be to provide or support such evi-
dence. In the case of “me-too” drugs,
it should be clear whether there are
other advantages.
Methods
Participants: Item 3. Eligibility crite-
ria for participants (detailing whether
participants in the noninferiority or
equivalence trial are similar to those in
any trial[s] that established efficacy of the
reference treatment) and the settings and
locations where the data were collected.
Example. “From Sept 1, 1992, to Dec
30, 1994, we enrolled 6628 men and
women in 312 health centres in
Sweden . . . who had hypertension
(blood pressure 180 mm Hg sys-
tolic,105 mm Hg diastolic, or both),
aged 70-84 years. The only difference
in inclusion criteria between this trial
and the STOP-Hypertension trial was
that patients with isolated systolic hy-
pertension could be included in STOP-
Hypertension-2, based on previous
positive findings in patients with iso-
lated systolic hypertension treated with
diuretics and calcium antagonists.”56
Elaboration.Relevant changes in par-
ticipants’ characteristics compared with
previous trial(s) should be reported and
explained. Clinical trial participants dif-
fer, mainly if time has elapsed between
trials; therefore, such description should
concentrate in relevant departures (that
might affect response to treatments).
Interventions: Item 4. Precise de-
tails of the interventions intended for
each group, detailing whether the refer-
ence treatment in the noninferiority or
equivalence trial is identical (or very simi-
lar) to that in any trial(s) that estab-
lished efficacy, and how and when they
were actually administered.
Example. “[W]e randomly assigned
women about to deliver vaginally to re-
ceive 600 µg misoprostol orally or 10 IU
oxytocin intravenously or intramuscu-
larly, according to practice. . . . The use
of uterotonic agents [oxytocin, a type of
uterotonic, is the reference treatment]
in the management of the third stage of
labour reduces the amount of bleeding
and the need for blood transfusion . . . ”57
(The authors reference a Cochrane
systematic review, showing that utero-
tonic agents reduced bleeding and blood
transfusions compared with placebo.)
Elaboration. Any differences be-
tween the control intervention in the trial
and the reference treatment in the pre-
vious trial(s) in which efficacy was es-
tablished should be reported and ex-
plained. For example, differences may
exist because background treatment and
patient management change with time
and concomitant therapies may dif-
fer.27 Dose changes may occur: if the dose
of the reference treatment is reduced, it
might result in reduced efficacy; if it is
increased, possibly leading to tolerabil-
ity problems, the new treatment’s ad-
vantages could be overestimated.
Objectives: Item 5. Specific objec-
tives and hypotheses, including the hy-
pothesis concerning noninferiority or
equivalence.
Example. “[A] bodyweight-adjusted
single bolus of 0.50-0.55 mg/kg te-
necteplase would be equivalent to a 90
min regimen of alteplase for efficacy and
safety [the primary endpoint for effi-
cacy was all-cause 30-day mortality
from acute myocardial infarction]. In
this double-blind, randomised, con-
trolled study, we formally tested this
hypothesis.”13
Elaboration. The authors should
specify for which outcomes noninferi-
ority or equivalence hypotheses apply
and for which superiority hypotheses
apply. Usually the noninferiority or
equivalence hypothesis refers to the
primary end point, whereas the new
treatment is expected to offer other
advantages, eg, fewer adverse effects,
cost.
Outcomes: Item 6. Clearly defined
primary and secondary outcome mea-
sures, detailing whether the outcomes in
the noninferiority or equivalence trial
are identical (or very similar) to those in
any trial(s) that established efficacy of
the reference treatment and, when
applicable, any methods used to
enhance the quality of measurements
(eg, multiple observations, training of
assessors).
Example. “Over the past decade seven
large, randomised, placebo-controlled
trials involving a total of 16,770 pa-
tients who underwent percutaneous in-
terventions have established that the
overall reduction in the risk of death or
nonfatal myocardial infarction 30 days
after adjunctive inhibition of platelet
glycoprotein IIb/IIIa receptors is 38 per-
cent. Three glycoprotein IIb/IIIa inhibi-
tors were assessed in these trials. The
primary end point [in the present trial]
was a composite of death, nonfatal myo-
cardial infarction, or urgent target-
vessel revascularization within 30 days
after the index procedure.”58
Elaboration. Any differences in out-
come measures in the new trial com-
pared with trial(s) that established ef-
ficacy of the reference treatment should
be noted and justified. In particular,
note any changes in timing of evalua-
tion. Ideally, outcomes should remain
unchanged, but often insights do lead
to change as the understanding, man-
agement, and prognosis of a disease im-
prove. For example, early AIDS trials
used death outcomes, then deaths be-
came uncommon, so they shifted to
AIDS clinical events, then clinical events
became uncommon, so they shifted to
surrogate markers.
Sample Size: Item 7a. How sample
size was determined, detailing whether
it was calculated using a noninferiority
or equivalence criterion, and specifying
the margin of equivalence with the ratio-
nale for its choice.
Examples. “Considering previous
studies, a primary event rate of 3.1% per
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year was estimated for patients in both
treatment groups. To obtain 90% sta-
tistical power with a 1-sided  equal to
0.025, approximately 1600 patient-
years of exposure per treatment groups
are necessary to establish the noninfe-
riority of ximelagatran compared with
dose-adjusted warfarin within 2% per
year. . . . Assuming an average follow up
of 16 months, approximately 2400 pa-
tients are required.”59
“Sample size was based on . . . [an]
8.0% primary quadruple end point event
rate in the control (heparin plus Gp IIb/
IIIa blockade) group [reference treat-
ment] and a 12.5% relative reduction in
the bivalirudin arm. Using a 2-sided 
level of .05 and 3000 patients per group,
the trial had a 99% power to detect su-
periority over the imputed heparin con-
trol [historical control] and a 92% power
to satisfy noninferiority criteria relative
to heparin plus Gp IIb/IIIa.”46
Elaboration. The margin of noninfe-
riority or equivalence should be speci-
fied, and preferably justified on clini-
cal grounds. Its relation to the effect of
the reference treatment relative to pla-
cebo in any previous trials should be
noted (see second example).
Sample size calculations are usually
based on the assumption that the point
estimate of the difference between treat-
ments will be 0 (as in the first ex-
ample above). Examples F and G in the
Figure would have met the noninferi-
ority criterion had the observed point
estimates been 0. That is, the preci-
sion of the estimates would have been
adequate, had the 2 treatments been
equally effective. With a large enough
sample, it is possible to demonstrate
noninferiority even when the point es-
timate is between 0 and . If the true
effect is assumed to be greater than 0,
the sample size will need to be in-
creased, perhaps substantially.
Stopping Rules: Item 7b. When ap-
plicable, explanation of any interim
analyses and stopping rules (and
whether related to a noninferiority or
equivalence hypothesis).
Example. “Interim safety analyses
were planned when 40 and 70 percent
of the total number of women had been
enrolled. An increased rate of HIV trans-
mission associated with the shorter regi-
mens, as compared with the long-long
regimen, would be considered signifi-
cant if any of the nominal P values for
the differences were less than 0.007 in
the first interim analysis and less than
0.012 in the second. . . . ”38
Elaboration. It is customary to base
interim stopping criteria on P values,
and these adjusted P values are analo-
gous to widened CIs.
Statistical Methods: Item 12. Sta-
tistical methods used to compare groups
for primary outcome(s), specifying
whether a 1- or 2-sided confidence inter-
val approach was used. Methods for ad-
ditional analyses, such as subgroup
analyses and adjusted analyses.
Examples. Binary outcome. “The pro-
portion of the intention-to-treat popu-
lation experiencing primary events per
year for both treatment groups, and the
associated 1-sided 97.5% CI for the dif-
ference, will be estimated using the time
to first event . . . The noninferiority mar-
gin () defined in the primary analysis
is based on absolute event rate
differences . . . Noninferiority of ximela-
gatran over warfarin will be accepted [in
a 0.025 level test] if the upper bound of
the 97.5% CI around the estimated dif-
ference in primary event rates lies be-
low . For these studies, an absolute 
of 2% was adopted. . . . ”59
Continuous outcome. “Regimens were
regarded as equivalent if the differ-
ence between treatments in change in
FEV1 (using 95% CI) was less than 4%
of predicted FEV1 . . . Since we were
undertaking an equivalence study, the
primary analysis was per protocol but
an intention-to treat analysis was also
undertaken. The mean difference be-
tween treatments and 95% CI for the
true difference was obtained from analy-
sis of variance, with adjustment for cen-
tre and type of clinic. . . . ”15
Elaboration. The upper bound of the
1-sided (1−)100% CI (or corre-
spondingly, the upper bound of the
2-sided (1−/2)100% CI) for the
treatment effect has to be below the mar-
gin  to declare that noninferiority has
been shown, with a significance level.
Both  and  should be prespecified in
the noninferiority hypothesis.
Results
Numbers Analyzed: Item 16. Num-
ber of participants (denominator) in
each group included in each analysis
and whether “intention-to-treat” and/or
alternative analyseswere conducted. State
the results in absolute numbers when
feasible (eg, 10/20, not just 50%).
Example. “Efficacy variables were
analyzed on an intent-to-treat ba-
sis . . . and on an as-treated basis. In the
intent-to-treat analysis, patients were
considered treatment failures if they
made any treatment changes, prema-
turely discontinued randomized treat-
ment for any reason, or had missing
data for 2 consecutive evaluations. In
the as-treated analysis, only data from
patients continuing randomized treat-
ment were considered for analysis.”60
Outcomes and Estimation: Item 17.
For each primary and secondary out-
come, a summary of results for each
group and the estimated effect size and
its precision (eg, 95% confidence in-
terval).For the outcome[s] forwhich non-
inferiority or equivalence is hypoth-
esized, a figure showing confidence
intervals andmargins of equivalencemay
be useful.
Examples. Inferiority of new treat-
ment, figure legend. “Relative risk of
blood loss of 1000 mL or more with mi-
soprostol compared with oxytocin
[1.39, 95% CI 1.19 to 1.63]. Vertical
dotted lines represent margins of clini-
cal equivalence determined a priori
[0.74 and 1.35 on the relative scale].
Solid line represents null effect.”57
(AfiguresimilartocaseGintheFigure
was presented on the relative scale.)
Noninferiority of new treatment.
“The primary quadruple composite
end point of death, myocardial infarc-
tion, urgent repeat revascularization,
or in-hospital major bleeding by 30
days occurred in 299 (10.0%) of 2991
patients in the heparin plus Gp IIb/IIIa
inhibitor group vs 275 (9.2%) of 2975
patients in the bivalirudin group (OR,
0.92; 95% CI, 0.77-1.09; P=0.32).
Relative to heparin alone, the imputed
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OR was 0.62 (95% CI, 0.47-0.82), sat-
isfying statistical criteria for non-
inferiority to heparin plus Gp IIb/IIIa
blockade and superiority to heparin
alone.”46
(A figure similar to case B in the
Figure was presented on the relative
scale but without the margin of
noninferiority.)
Elaboration. In the first example the
new treatment was inferior, but it was
uncertain whether the treatment effect
was smaller or larger than the margin
of equivalence 1.35. The second ex-
ample demonstrated noninferiority.
Comment
Interpretation: Item 20. Interpreta-
tion of the results, taking into account
the noninferiority or equivalence
hypothesis and any other trial hypoth-
eses, sources of potential bias or
imprecision and the dangers associ-
ated with multiplicity of analyses and
outcomes.
Examples. Concluding noninferiority.
“According to our definition of equiva-
lence, the efficacy of the . . . long-
short regimen (was) statistically equiva-
lent to the efficacy of the long-long
regimen . . . The upper limit of the 95
percent confidence interval for the dif-
ference between the rates in the two
groups was 5.3 percent (close to the
boundary of 6.0 percent).”38
Concluding inferiority of new drug
(or conventional superiority of refer-
ence drug). “Although the trial was
intended to assess the noninferiority
of tirobifan as compared with abcix-
imab, the findings demonstrated that
tirobifan offered less protection from
major ischemic events than did
abciximab. . . . In order to meet the
present definition of equivalence, the
upper bound of the 95% confidence
interval of the hazard ratio for the
comparison of tirofiban with abcix-
imab had to be less than 1.47. . . . The
primary endpoint occurred more fre-
quently among the 2398 patients in
the tirofiban group than among the
2411 patients in the abciximab group
(7.6 percent vs. 6.0 percent; hazard
ratio, 1.26; . . . two-sided 95 percent
confidence interval of 1.01 to 1.57,
demonstrating the superiority of
abciximab over tirofiban; P=0.038).”58
Concluding noninferiority of new drug
froma trial designed to assess superiority.
“The SYNERGY protocol prespecified
that if enoxaparin was not demon-
strated to be superior to unfraction-
ated heparin, a noninferiority analysis
was to be performed. . . . Enaxoparin
was not superior to unfractionated hep-
arin but was noninferior for the treat-
ment of high-risk patients with non-
ST-segment elevation ACS.”44
Comment
It is not our intent to promote nonin-
feriority or equivalence trials: the de-
sign should be appropriate to the ques-
tion to be answered.21 Available
efficacious reference treatments can
make use of placebo controls unethi-
cal.61 But even in cases for which a treat-
ment is efficacious on some measures,
eg, depression scales, it may not be for
a rarer but more important outcome,
eg, suicide.62 Reports of noninferiority
and equivalence trials must be clear
enough to allow readers to interpret re-
sults reliably. Accordingly, we herein
propose extensions to the CONSORT
statement to facilitate appropriate re-
porting of noninferiority and equiva-
lence trials.
We advocate that editors extend
support of the original CONSORT
statement to include use of this exten-
sion to noninferiority and equivalence
trials and refer to it in their “Instruc-
tions to Authors.” Adoption by jour-
nals of the original CONSORT state-
ment is associated with improved
quality,63-65 so we hope this proposed
extension will result in similar
improvements for noninferiority and
equivalence trials.
The CONSORT Group continues to
update and extend its recommenda-
tions. The current recommendations add
to recent extensions to cluster random-
ized trials,66 and the reporting of harms.4
Further extensions are in preparation.
The current versions of all CONSORT
recommendations are available at http:
//www.consort-statement.org.
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CORRECTIONS
Incorrect Formula: In the Special Communication entitled “Reporting of Nonin-
feriority and Equivalence Randomized Trials: An Extension of the CONSORT
Statement” published in the March 8, 2006, issue of JAMA (2006;295:1152-
1160), a formula for a 2-sided confidence interval (CI) used to assess noninferi-
ority of a new treatment compared with a standard one with regard to an out-
come was incorrect. On page 1158 in the subsection titled “Elaboration” that
reads “the upper bound of the 2-sided (1−/2)100% CI for the treatment
effect has to be below the margin  to declare that noninferiority has been
shown . . . ” should read “the upper bound of the 2-sided (1 −2)100% CI
for the treatment effect has to be below the margin  to declare that noninferi-
ority has been shown . . . ”
Error in Figure: In the Original Contribution entitled “Long-term Renal Outcomes
in Patients With Primary Aldosteronism” published in the June 14, 2006, issue of
JAMA (2006;295:2638-2645), an error occurred in FIGURE 3. In the left panel, which
reports creatinine clearance values, the scale of the y-axis is not correct, and the
data are therefore not plotted correctly. The correct graph appears below.
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